Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Neuromorphic Computing Market worth $1,325.2 million by 2030 - Exclusive Report…

Browse in-depth TOC on "Neuromorphic Computing Market" 167 – Tables69 – Figures256 – Pages Browse in-depth TOC on "Neuromorphic Computing Market" 167 – Tables 69 – Figures 256 – Pages Neuromorphic Computing Market Report Scope: By Offering, software segment is projected to grow at a high CAGR of neuromorphic computing market during the forecast period. The software segment is expected to grow at a fast rate in the forecasted period. Neuromorphic software has its roots in...

Orexo initiates new study of OX640 in participants with allergic rhinitis

The study is a cross-over study in 30 participants with allergic rhinitis and involves four treatment periods. In one of the periods, a small dose of an allergen will be sprayed into the nose of the participants to trigger an allergic reaction before being treated with OX640. This will be compared with absorption of epinephrine from OX640 without the allergen, and a commercial intramuscular epinephrine product. The fourth period will be used to document dose proportionality of OX640. In addition…

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presenting at the conference on Tuesday, November 19, 2024 at 9:00-9:25 am GMT.An audio webcast of the conference presentation will also be available to...

Endo Announces Peyronie's Disease Presentation at the SurgeWest Annual Meeting…

The Endo-supported research presentation is below: The Endo-supported research presentation is below: About the Post Hoc Phase 3 Data Analysis 1 A post hoc analysis of pooled data from two randomized, double-blind, placebo-controlled Phase 3 trials was conducted to evaluate CCH treatment and improvement in penile curvature in participants presenting with/without penile pain at baseline and disease duration of 12–18 months or >18 months. CCH-treated participants were stratified by...

Invitation: Sobi's Aspaveli® and the Phase 3 VALIANT data in Nephrology call

Investors, analysts, and members of the media are invited to a conference call on Tuesday, October 29th, at 12:00 CET, 11:00 GMT, and 07:00 EDT. The call will include a presentation of results and insights from management and Professor Fadi Fakhouri following the American Society of Nephrology (ASN) and a Q&A session. Investors, analysts, and members of the media are invited to a conference call onTuesday, October 29th, at12:00 CET,11:00 GMT, and07:00 EDT. The call will include a...

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at…

Presentations highlight key preclinical data that support investigational new drug application (IND) submissions for ZW220 in 1H and ZW251 in 2H in 2025VANCOUVER, British Columbia, Oct.25, 2024(GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks' antibody-drug...

Microencapsulation Market worth $24.07 billion by 2029 - Exclusive Report by…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=83597438 Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=83597438 Browse in-depth TOC on "Microencapsulation Market" 250 – Tables 80 – Figures 350 – Pages The Food & Beverage Ingredients is the having a significant share within the Core Material sector of the microencapsulation market. Increasing demand for functional and fortified food products...

Clock Change Chaos: 40% of Shift Workers Struggle with Sleep as Clocks Go Back

These challenges extend beyond the clock change, with 49% of shift workers experiencing winter energy dips due to shorter daylight. As a result, 40% rely on energy drinks to stay alert and 14% admit to consuming four or more per shift, raising concerns about energy crashes and sugar intake. These challenges extend beyond the clock change, with 49% of shift workers experiencing winter energy dips due to shorter daylight. As a result, 40% rely on energy drinks to stay alert and 14% admit to...

Meret Gaugler, PhD, joins Page Therapeutics as independent member of the Board…

"Meret will bring us invaluable strategic insights as we are moving from an early-stage discovery company to a structured biotech, preparing our drug candidate for clinical trials" commented Nicola Aceto, Professor of Molecular Oncology at ETH Zurich and Page's scientific founder. "Our innovative approach targeting the dissociation of circulating tumour cell clusters to inhibit their potential to form metastases needs a strict development process as well as long term vision and…

Bridge to Life and ULS Coimbra Announce Collaboration to Enhance Preservation of…

The initiative kicks off with the development and launch of a case study demonstrating the important organ transplantation research and procedures being conducted at ULS Coimbra. The initiative kicks off with the development and launch of a case study demonstrating the important organ transplantation research and procedures being conducted at ULS Coimbra. "Bridge to Life is excited to support the innovations and advancements in organ transplantation at ULS Coimbra and look forward to...

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated…

Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performanceParis, October 25, 2024Q3 sales growth of 15.7% at CER and business EPS (1)of €2.86Dupixent sales up 23.8% to €3,476 million; full-year 2024 target of ~€13 billion confirmedPharma launches up 67.1% to €727 million, led by ALTUVIIIO, Nexviazyme and RezurockVaccines sales up 25.5%, boosted by phasing of flu sales, and by...

Independent meta-analyses by Melanoma Institute of Australia on CP-GEP model in…

The MIA-led study analyzed data from independent external validation studies on the Merlin CP-GEP model published between 2020 and 2024. These studies spanned patient records from 4 countries, offering a comprehensive view of the model's predictive accuracy. The analysis revealed that the CP-GEP model achieved a sensitivity of 93%, meaning it accurately identified 93% of patients with nodal metastasis, while achieving an NPV (Negative Predictive Value) of 95%, indicating that 95% of patients…

Global Protein Chip Market to Surge at a CAGR of ~7% by 2030 | DelveInsight

Key Takeaways from the Protein Chip Market Report Key Takeaways from the Protein Chip Market Report To read more about the latest highlights related to the protein chip market, get a snapshot of the key highlights entailed in the Global Protein Chip Market Report Protein Chip Overview A protein chip, also known as a protein microarray, is a high-throughput platform used to study protein interactions, function, and expression on a large scale. It consists of thousands of...

IVD Assay Development Market to be Worth $8.39 Billion by 2031--Exclusive Report…

The IVD assay development market is projected to reach $8.39 billion by 2031, at a CAGR of 7.9% from 2024 to 2031. The IVD assay development market is projected to reach$8.39 billionby 2031, at a CAGR of 7.9% from 2024 to 2031. Download FREE PDF Brochure Of IVD Assay Development Market - https://www.meticulousresearch.com/download-sample-report/cp_id=6037 In vitro diagnostics (IVD) assay development services provide comprehensive, end-to-end contracting solutions. These services...

Pediatric Orphan Drug Market Size to Grow USD 102180 Million by 2030 at a CAGR…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-26J17580/Global_Pediatric_Orphan_Drug_Market_Research_Report_2024 Get Free Sample :https://reports.valuates.com/request/sample/QYRE-Auto-26J17580/Global_Pediatric_Orphan_Drug_Market_Research_Report_2024 Major Factors Driving the Growth of Pediatric Orphan Drug Market: The Pediatric Orphan Drug Market is poised for significant growth in the coming years as the demand for specialized treatments for rare pediatric...

Inside information: Orion terminates ODM-111 development program due to narrow…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – INSIDE INFORMATION 24 OCTOBER 2024 at 19.50 EEST Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule Orion Corporation has decided to terminate the ODM-111 development program based on the risk-benefit analysis on the results of a longer non-clinical toxicology study. Recent findings indicate that the profile of the ODM-111 molecule does not support long-term use of ODM-111...

GUERBET : Revenue at September 30, 2024.

Revenue at September 30, 2024Continued growth momentum 9-month revenue: €620.5m, up 9.6% at CER 1 In the third quarter, momentum remained strong (+5.4% at CER), driven by the Americas (+13.1%) and Asia (+8.1%), while performance in EMEA (-2.3%) was once again impacted by the continued implementation of the new supply chain in France2024 annual targets confirmedRevenue: expected growth of over 9% on a like-for-like basis and at CERProfitability:...

ONWARD® Medical Publishes Prospectus for Listing of New Shares

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)EINDHOVEN, the Netherlands, Oct.24, 2024(GLOBE NEWSWIRE) --ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today that it has published a...

Organoids Market Size To Reach $15.01 Billion By 2031 | CAGR 22.3%: The Insight…

Browse Detailed Analysis: https://www.theinsightpartners.com/reports/organoids-market Browse Detailed Analysis:https://www.theinsightpartners.com/reports/organoids-market Overview of Report Findings Market Growth : The organoid market is expected to reach U.S. $ 15.01 billionby 2031 from U.S. $ 3.03 billionin 2023, registering a CAGR of 22.1% during the forecast period. Organoids are microscopic and self-organized 3D structures produced in vitro from stem cells. They...

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of…

BIOVAXYS PROVIDES PRIVATE PLACEMENT UPDATES

Publication relating to transparency notifications

NeoMab Fully Human Antibody Discovery Platform: A New Flexible Mouse Purchase…

Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv

Neuromorphic Computing Market worth $1,325.2 million by 2030 - Exclusive Report…

Orexo initiates new study of OX640 in participants with allergic rhinitis

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London…

Endo Announces Peyronie's Disease Presentation at the SurgeWest Annual Meeting…

Invitation: Sobi's Aspaveli® and the Phase 3 VALIANT data in Nephrology call

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at…

Microencapsulation Market worth $24.07 billion by 2029 - Exclusive Report by…

Clock Change Chaos: 40% of Shift Workers Struggle with Sleep as Clocks Go Back

Meret Gaugler, PhD, joins Page Therapeutics as independent member of the Board…

Bridge to Life and ULS Coimbra Announce Collaboration to Enhance Preservation of…

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated…

Independent meta-analyses by Melanoma Institute of Australia on CP-GEP model in…

Global Protein Chip Market to Surge at a CAGR of ~7% by 2030 | DelveInsight

IVD Assay Development Market to be Worth $8.39 Billion by 2031--Exclusive Report…

Pediatric Orphan Drug Market Size to Grow USD 102180 Million by 2030 at a CAGR…

Inside information: Orion terminates ODM-111 development program due to narrow…

GUERBET : Revenue at September 30, 2024.

ONWARD® Medical Publishes Prospectus for Listing of New Shares

Organoids Market Size To Reach $15.01 Billion By 2031 | CAGR 22.3%: The Insight…